We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Zai Lab Limited (ZLAB) ADS Each Repr 10 Ord Shares

Sell:$19.51 Buy:$23.10 Change: No change
Market closed |  Prices as at close on 23 February 2024 | Switch to live prices |
Change: No change
Market closed |  Prices as at close on 23 February 2024 | Switch to live prices |
Change: No change
Market closed |  Prices as at close on 23 February 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Zai Lab Ltd is a holding company mainly engaged in the biopharmaceutical field. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including oncology, autoimmune and infectious diseases fields. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include Niraparib (ZL-2306), ZL-2103, ZL-1101 and others.

Contact details

4560 Jinke Road, Bldg. 1, 4/F, Pudong
+86 (21) 61632588

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$1.98 billion
Shares in issue:
969.04 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Du Ying
    Chairman of the Board, Chief Executive Officer, Co-Founder
  • Joshua Smiley
    President, Chief Operating Officer
  • Yajing Chen
    Chief Financial Officer
  • Rafael Amado
    President - Global Oncology Research and Development
  • Harald Reinhart
    President, Head - Global Development of Neuroscience, Autoimmune and Infectious Diseases
  • F. Ty Edmondson
    Joint Company Secretary, Chief Legal Officer
  • Au-yeung Nelly
    Joint Company Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.